Milestone Pharmaceuticals (NASDAQ:MIST) has officially moved into the commercial stage with the U.S. retail launch of Cardamyst™ (etripamil).
The nasal spray is now available across pharmacies nationwide, offering a long-awaited alternative to emergency room visits for adults suffering from paroxysmal supraventricular tachycardia (PSVT).
Approved by the FDA on December 12, 2025, Cardamyst is the first therapy for PSVT to hit the market in more than 30 years.
PSVT is a condition characterized by sudden, rapid heartbeats—often exceeding 150 to 200 beats per minute—that can cause significant distress, shortness of breath, and fainting.
Historically, patients experiencing an episode had few options: attempt vagal maneuvers (such as bearing down) or seek immediate care at an emergency department for intravenous medication.
Cardamyst changes this paradigm by providing a fast-acting calcium channel blocker in a portable, single-use nasal spray.
Milestone is currently deploying a national sales force to drive physician awareness, with full deployment expected by mid-February 2026.
To lower the barrier to adoption, the company has launched a patient assistance platform.
For eligible patients with commercial insurance, the company is capping copays at $25.
This initiative is part of a broader strategy to ensure affordability as Milestone continues negotiating with insurers for broad formulary coverage.